AKBA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Based on the data provided, Akebia Therapeutics Inc (AKBA) is not a strong buy for a beginner, long-term investor at this time. The stock has shown significant recent price declines, lacks strong positive catalysts, and has no proprietary trading signals indicating a buy opportunity. While the company has shown revenue growth, its net income and EPS have significantly declined, which raises concerns about profitability. Analysts have lowered price targets, and trading sentiment remains neutral. Given these factors, it is advisable to hold off on purchasing this stock for now.
The technical indicators show a neutral to bearish trend. The RSI is at 37.873, indicating no clear signal but leaning towards oversold territory. The MACD is slightly positive but contracting, suggesting limited momentum. The stock price is below its pivot level (1.44) and close to its first support level (1.327), indicating potential weakness.
The company has initiated a Phase 1 clinical trial for AKB-9090, which could be a long-term positive catalyst if successful. Revenue growth of 23.93% YoY in Q4 2025 is also a positive indicator.
Significant price decline of -12.90% in the regular market session and further declines in pre- and post-market trading. Analysts have lowered price targets due to lower-than-expected revenue from Vafseo. Net income and EPS have significantly declined YoY, raising concerns about profitability.
In Q4 2025, revenue increased by 23.93% YoY to $57.62M, but net income dropped by -46.31% YoY to -$12.24M. EPS also fell by -50% YoY to -$0.05. Gross margin improved to 82.06%, up 41.56% YoY, indicating better cost efficiency but not enough to offset declining profitability.
Analysts have recently lowered price targets from $5 to $4 and from $6 to $4, citing lower-than-expected revenue and inventory issues. However, they maintain a Buy and Overweight rating, indicating cautious optimism.
